AACR 2016: Report of the annual meeting of the American Association for Cancer Research. Oncologie vol 18, July 2016.
APREC participated to the AACR congress 2016 which took place in New Orleans. APREC coordinated the scientific writing of the meeting report. The work was in collaboration with the French medical journal Oncologie and helped by medical students from the association AERIO.
APREC researchers presented their work at the meeting of the American Association for Cancer Research in New Orleans, U.S
During the poster session at the AACR meeting, APREC researchers presented their clinical study entitled: High-dose chemotherapy associated with bevacizumab for metastatic germ-cell tumors: the TAXIF 3 trial. This is a clinical trial in progress that was set up with the aim to improve outcomes of germ cell tumor patients with relapsed or refractory disease who do not respond to other available treatments.
APREC team participated in the Franco-Serbian Congress of Oncology in Novi Sad, Serbia
The Medical Oncology Service of the Tenon Hospital and the Institute of Oncology in Vojvodina (IOV, Novi Sad – Serbia) established in November 2007 their first collaboration, 9 months after the first visit of Professor Jean-Pierre Lotz (head of the scientific board of APREC) in Belgrade. This travel was requested by the French Ministry of Foreign Affairs as part of a large program to help Serbia developed by the French President Jacques Chirac.
In 2008, Pr Lotz help Serbian colleagues to create the first French-Serbian Congress of Medical Oncology, dedicated to breast cancer. Given the success of this first meeting, this event became annual. Each year about ten French doctors participated in this project.
In 2016, nearly 200 participants signed to the 7th meeting which had speakers from all over the world including Greece, Italy, Israel, China, USA, Serbia and France.
The theme of this 7th meeting was that “metastatic diseases”. During the meeting, a student session with the participation of internal medical students from France and Serbia allow the young doctors to present their works for the first time in an international congress. High quality conferences included the Darwinian and mathematical aspects of tumor growth and development of drug resistance took place.
The 8th Congress is expected in March 2017 and will be dedicated to cancer immunotherapy.
Year 2015 represented for APREC positive results with 26 scientific publications in international journals referenced in the PubMed database records.
1st Symposium RéCaP: Réseau Cancer des Points Cardinaux.
APREC researchers have organized and participated in the first meeting RéCaP. The Réseaux Cancer des Point Cardinaux is an oncology network of 10 French institutions (public/private) located around the Tenon Hospital, Paris. The aims of the network are (1) to create a link between institutions to allow patients participations in clinical trials and (2) to promote continuous education of the medical community through promotion of meetings, seminars and research collaborations.
AACR 2015: Report of the annual meeting of the American Association for Cancer Research. Oncologie vol 17, Issue 7, July 2015.
APREC participated to the AACR congress 2015 which took place in Philadelphia from April 18-22. As a result, APREC coordinated the scientific writing of the meeting report. The work was in collaboration with the French medical journal Oncologie and helped by medical students from the association AERIO.
It was a five-day multidisciplinary program covering all aspects of cancer science from basic to translational as well as to clinical research. The meeting highlighted the latest and most exciting findings, including new personalized medicines developed thanks to the genetic characterization of the tumors.
Efficacy and safety of bevacizumab in the randomized phase III IMELDA and TANIA clinical trials. Oral presentation ESMO 2014.
During the Proffered Paper session in Metastatic Breast Cancer at ESMO Congress 2014 in Madrid, Dr Joseph GLIGOROV, APREC researcher member, presented results of the IMELDA and TANIA randomized phase III clinical trials in HER2-negative metastatic breast cancer.
In the IMELDA study, adding capecitabine to maintenance bevacizumab for the treatment of HER2-negative patients with locally recurrent/metastatic breast cancer provided statistically significant and clinically meaningful improvements in progression-free survival and overall survival. During the trial, an increase in adverse events mainly due to hand-foot syndrome (experienced in 33% of patients in bevacizumab/capecitabine arm) was observed. However, these events were manageable. Dr Gligorov concluded that in patients benefiting from first-line bevacizumab-containing therapy, continued bevacizumab with capecitabine improves efficacy. Ongoing evaluation considers collection of data on anti-cancer treatment after study therapy and patient-reported outcomes.
The open-label randomized phase III TANIA study evaluated further bevacizumab in bevacizumab-pretreated locally recurrent/metastatic breast cancer. Patients with HER2-negative locally recurrent/metastatic breast cancer who had progressed during/after ≥12 weeks of first-line bevacizumab plus chemotherapy were randomised 1:1 to second-line single-agent chemotherapy either alone or with bevacizumab (15 mg/kg q3w or 10 mg/kg q2w). The primary objective of TANIA was also met. The trial showed statistically significantly improvement in progression-free survival (PFS) with bevacizumab after progression on first-line bevacizumab-containing therapy. Second-line safety results were as expected from previous bevacizumab trials in locally recurrent/metastatic breast cancer. Final overall survival, PFS from randomisation to third-line progression/death and third-line safety results are anticipated in mid 2015.
High-doses of chemotherapy to treat germ cell tumors: an option for patients who do not respond to standard treatment. Article published in Annals of Oncology.
APREC team recently wrote a research article reporting results of a clinical trial named TAXIF II which was published in the renowned international journal Annals of Oncology. This paper describes the results of the TAXIF II program, an alternative treatment for germ-cell tumor patients failing cisplatin-based chemotherapy. In this program, patients received high-doses of chemotherapy supported by autologous hematopoietic stem-cell transplantation. In conclusion, the treatment with TAXIF II was considered effective for relapsing non-refractory patients and can be used as an alternative option for salvage treatment after failure of one or two lines of chemotherapy. However, for refractory patients or those who tumors progress during therapy, other salvage treatment strategies clearly must be explored. In that sense, a new trial has been designed and is currently under evaluation. The TAXIF III, evaluating chemotherapy in combination with targeted-therapy may overcome chemotherapy resistance and improve responses rates for refractory-patients.